Recruiting Alzheimers Disease Studies in Melbourne
A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memo...
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participant...
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild t...
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (...
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or D...
About Alzheimers Disease Clinical Trials in Melbourne
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 7 alzheimers disease clinical trials recruiting participants in Melbourne, FLORIDA. These studies are seeking a combined 1,520 participants. Research is being sponsored by D3 Bio (Wuxi) Co., Ltd, Merck Sharp & Dohme LLC, AstraZeneca and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Melbourne — FAQ
Are there alzheimers disease clinical trials in Melbourne?
Yes, there are 7 alzheimers disease clinical trials currently recruiting in Melbourne, FLORIDA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Melbourne?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Melbourne research site will contact you about next steps.
Are clinical trials in Melbourne free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Melbourne studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 7 active trials in Melbourne are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov